Skip to main content
Fig. 1 | Alzheimer's Research & Therapy

Fig. 1

From: Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis

Fig. 1

Marked and consistent reduction of amyloid load in patients receiving high-dose gantenerumab. a Marked reduction of amyloid-β plaques in patients receiving high-dose gantenerumab, and consistent reduction of amyloid-β plaques in all patient groups. b Reduction of amyloid-β plaque burden to below positivity threshold following high-dose gantenerumab. aAnalyzed using a mixed model for repeated measures

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193